SGMT · Sagimet Biosciences
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $8.00
Note written ·
Price against the kill line
27.8% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $8.00, on record since 10 November 2026. The shares are down 2.0% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $8.00, which would put the shares well under the $10.00 September offering price and the 50-day moving average. Withdrawn funding guidance or AURORA topline timing pushed beyond the second half of 2027 would also break the case.
Research onlyNot in the portfolio.
The business · as of
Sagimet is a clinical-stage biotech developing denifanstat, an oral fatty acid synthase inhibitor, for acne and liver disease. It has no product sales; China rights are licensed to Ascletis. The net loss was $19 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 Sagimet extended its cash runway guidance from through 2028 to mid-2029 and kept AURORA Phase 3 topline results in the second half of 2027.
- What follows for the company
- Research and development expense rose to $16.3 million in the quarter to 30 September 2026 from $9.7 million a year earlier, as AURORA enrolls; cash was $275.8 million.
- What follows for its customers, suppliers and competitors
- Ascletis (HKEX 1672) holds Greater China rights, and a China approval would pay Sagimet milestones and royalties. No customer or supplier is named in the filings.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 12 November 2026) the shares trade at P/B 2.6, with a market value of $637 million and an enterprise value of $361 million (no debt reported); EV/sales is not available and P/E is not meaningful. The price assumes AURORA succeeds, as revenue is zero.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026
- Net cash, cash less debt ($M)
- 276
All filed numbers
What Sagimet Biosciences reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −53.3 | −19.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +92.0 |
| Operating cash flow ($M) | −43.7 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 276 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 276 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 242 |
| Market value ($M) | 637 |
| Enterprise value, market value plus net debt ($M) no debt reported | 361 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.6 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 18.5% of shares outstanding sold short, 8.2 days of average trading to cover, +3.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $4.9M |
The thesis
Sagimet Biosciences' acne drug denifanstat is in a US Phase 3 trial, and the company guided on 12 November 2026 that its cash funds operations through mid-2029. That gives the shares a modest edge over the S&P 500. AURORA enrollment and the topline results, guided to the second half of 2027, settle the call.
The rating is Medium because the trial and funding facts are dated and positive, while no US efficacy data is due for about a year. The shares closed at $10.22 on 13 November 2026, down from $10.93 on 12 November 2026 and $11.41 on 11 November 2026, and still above the $10.00 price of the 30 September 2026 offering. The published kill line has not been crossed.
The third-quarter report, filed on 12 November 2026 as an 8-K and a 10-Q, moved the runway guidance from "through 2028" to mid-2029, which the company says includes the AURORA readout and a potential US approval filing. Cash, cash equivalents and marketable securities were $275.8 million at 30 September 2026, and the net loss was $19.1 million, against $12.9 million a year earlier. Benzinga reported pro forma cash and investments of about $356 million.
Bullish and bearish views on Sagimet Biosciences Inc.
The bull case on Sagimet Biosciences Inc. (SGMT), in brief: the US pivotal trial has started. The bear case: burn is rising with the trial.
Bull case
- The US pivotal trial has started. On 22 October 2026 Sagimet announced the first patient dosed in AURORA, a randomized, placebo-controlled Phase 3 trial of about 800 patients aged 12 and older. Topline results are expected in the second half of 2027, and the company repeated that timing on 12 November 2026.
- Year-long data holds up. The 52-week open-label extension of the Phase 3 ASC40-304 trial reported Investigator's Global Assessment success of 57%, a 72% fall in total lesions and a 77% fall in inflammatory lesions (company release, 30 September 2026).
- Funding runs to mid-2029. Cash and short-term investments were $276 million with no debt at 30 September 2026 (10-Q filed 12 November 2026). The $115.0 million offering of Series A shares and pre-funded warrants closed on 1 October 2026.
- Spending is going into the trial. Third-quarter research and development expense was $16.3 million, up from $9.7 million a year earlier (third-quarter results, 12 November 2026). The rise follows the AURORA start-up.
Bear case
- Burn is rising with the trial. The third-quarter net loss was $19.1 million, up from $13.9 million in the second quarter and $12.9 million a year earlier (company filings, 11 August 2026 and 12 November 2026). Net loss over the four quarters to 30 September 2026 was $53 million, and operating cash flow was –$44 million.
- The share count has roughly doubled. The diluted share count rose 92.0% from a year earlier in the quarter to 30 September 2026 (10-Q filed 12 November 2026). The 27 April 2026 offering placed 29,166,700 Series A shares at $6.00, and the 30 September 2026 offering priced units at $10.00.
- A director sold near current prices. Director George Kemble exercised 350,987 options at $6.36 and sold 350,987 shares at $10.23 on 14 August 2026 under a Rule 10b5-1 plan (SEC Form 4, filed 17 August 2026).
- No US efficacy data for about a year. AURORA topline results are guided to the second half of 2027, so the shares trade on enrollment, financing and China news until then.
- China approval has no date. China's National Medical Products Administration accepted the acne new drug application on 10 December 2025 and has given no decision date. An approval pays Sagimet milestones and royalties through licensee Ascletis, not product revenue.
Price setup
The shares closed at $10.22 on 13 November 2026, 10.7% below the 52-week intraday high of $11.45 set on 10 September 2026. The three-month change is –2.0%, measured from the $10.43 close on 17 August 2026. The 52-week closing low is $4.55, set on 30 March 2026, before the April offering.
As of the 13 November 2026 close the 50-day moving average was $9.88 and the 200-day moving average was $7.71, so the shares sit above both. Daily closes ran $9.85 on 6 November 2026, $10.83 on 9 November 2026, $10.89 on 10 November 2026, $11.41 on 11 November 2026 and $10.93 on 12 November 2026. No company release explains the 13 November 2026 decline. The 12 November 2026 and 13 November 2026 sessions gave back most of the week's gain, and the close now sits $0.22 above the $10.00 offering unit price.
Across US stocks trading at least $5 million a day, the spread of 63-session returns had a standard deviation of 27% in 2026. A single clinical-stage name can finish far from the index in either direction over three months.
Catalysts ahead
- Undated: China NMPA decision on the denifanstat acne NDA, accepted 10 December 2025. An approval would bring milestones and royalties through Ascletis and a first regulatory endorsement of the drug. A deficiency letter would weaken the evidence base before the US readout.
- Second half of 2027: AURORA Phase 3 topline results for denifanstat in moderate to severe acne. This is the first US efficacy readout and the event the mid-2029 funding guidance is built around.
What would change the view
A daily close below $8.00, which would put the shares well under the $10.00 September offering price and the 50-day moving average. Withdrawn funding guidance or AURORA topline timing pushed beyond the second half of 2027 would also break the case.
The risks this note tracks, each with what would confirm it:
- Burn rises faster than guided as AURORA enrolls, shortening the mid-2029 runway. Confirmed by: a quarterly net loss well above the $19.1 million reported for the third quarter, or changed runway language in the fourth-quarter report.
- Holders from the $6.00 April and $10.00 September offerings sell, pulling the shares under the offering price. Confirmed by: daily closes below the $10.00 unit price, after the $10.22 close on 13 November 2026.
- More insider sales near current prices. Confirmed by: new SEC Form 4 filings showing director or officer open-market sales.
- The China NMPA decision on the acne NDA is delayed or negative. Confirmed by: an Ascletis or Sagimet disclosure of a deficiency letter or rejection.
- AURORA enrollment slows, delaying the second-half 2027 topline. Confirmed by: a company update moving topline guidance beyond the second half of 2027.
What it trades with
Sagimet trades as a clinical-stage biotech. Its price follows financing events, trial milestones and Chinese regulatory news more than the broad market. Ascletis (Hong Kong: 1672), the China licensee, reports the Chinese acne data and regulatory steps, so its disclosures can move Sagimet. Risk appetite for small-cap biotech and interest-rate expectations act on the shares through the financing window: the company raised equity twice in 2026, in April and September.
The evidence, claim by claim (7)
- Cash, cash equivalents and marketable securities were $275.8 million at 30 September 2026; third-quarter net loss $19.1 million versus $12.9 million a year earlier; research and development expense $16.3 million versus $9.7 million. Sagimet Q3 2026 results, 8-K and 10-Q filed 12 November 2026 · as of
- Sagimet guided that cash funds operations through mid-2029, including the AURORA readout and a potential US approval application, extending the earlier guidance of through 2028. Sagimet Q3 2026 results, 12 November 2026 · as of
- Net loss was $53 million and operating cash flow was –$44 million over the four quarters to 30 September 2026; the diluted share count rose 92.0% from a year earlier. Sagimet 10-Q filed 12 November 2026 (SEC XBRL) · as of
- First patient dosed in AURORA, a US Phase 3 trial of denifanstat in about 800 acne patients aged 12 and older; topline results expected in the second half of 2027. Sagimet company release, 22 October 2026 · as of
- 52-week Phase 3 ASC40-304 open-label extension in acne: Investigator's Global Assessment success 57%, total lesions down 72%, inflammatory lesions down 77%. Sagimet company release, 30 September 2026 · as of
- Sagimet closed its underwritten offering of Series A common stock and pre-funded warrants for about $115.0 million in gross proceeds. Sagimet company release, 1 October 2026 · as of
- Director George Kemble exercised 350,987 options at $6.36 and sold 350,987 shares at $10.23 under a Rule 10b5-1 plan. SEC Form 4 filed 17 August 2026 · as of
Sources